Enovis (NYSE:ENOV) Price Target Cut to $33.00 by Analysts at Wells Fargo & Company

Key Points

• Wells Fargo cut Enovis’s price target to $33 from $39 but maintained an “overweight” rating, implying about 59.6% upside from the stock’s $20.67 price.
• Analyst sentiment remains broadly positive: Enovis has a consensus “Moderate Buy” rating from 12 analysts, with an average price target of $40.38 despite several recent target reductions.
• Enovis recently beat quarterly expectations, reporting $0.90 in earnings per share versus the $0.85 consensus and revenue of $582.78 million; insiders have also purchased shares in recent months.

Enovis (NYSE:ENOV - Get Free Report) had its target price decreased by investment analysts at Wells Fargo & Company from $39.00 to $33.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Wells Fargo & Company's target price would indicate a potential upside of 59.64% from the company's current price.

A number of other equities analysts have also recently weighed in on the stock. Weiss Ratings raised shares of Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 21st. BTIG Research cut their price target on Enovis from $40.00 to $36.00 and set a "buy" rating on the stock in a research note on Tuesday. Canaccord Genuity Group reduced their price target on Enovis from $50.00 to $45.00 and set a "buy" rating for the company in a report on Monday, August 17th. Zacks Research upgraded Enovis from a "strong sell" rating to a "hold" rating in a report on Wednesday, July 29th. Finally, Citigroup reiterated a "market outperform" rating on shares of Enovis in a research note on Wednesday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $40.38.

Enovis Trading Up 0.7%

NYSE:ENOV traded up $0.14 during trading hours on Wednesday, reaching $20.67. 330,259 shares of the company were exchanged, compared to its average volume of 1,091,172. Enovis has a 52-week low of $19.14 and a 52-week high of $34.28. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -1.07 and a beta of 1.32. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The stock has a 50 day simple moving average of $25.65 and a 200 day simple moving average of $24.27.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million during the quarter, compared to analysts' expectations of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm's revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts predict that Enovis will post 3.15 EPS for the current year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert acquired 1,200 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average price of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have bought 3,200 shares of company stock valued at $69,864. Insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Enovis

Institutional investors have recently made changes to their positions in the stock. Arax Advisory Partners bought a new stake in shares of Enovis in the 4th quarter worth approximately $29,000. Allworth Financial LP bought a new position in Enovis during the 2nd quarter worth $36,000. EverSource Wealth Advisors LLC grew its stake in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock worth $40,000 after buying an additional 707 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Enovis in the second quarter worth $48,000. Finally, Danske Bank A S acquired a new stake in Enovis in the third quarter worth $64,000. 98.45% of the stock is owned by institutional investors.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Citizens JMP maintained a “Market Outperform” rating on Enovis (ENOV) while lowering its price target from $55 to $47. The revised target still implies substantial upside from the recent share price, suggesting the analyst believes the selloff may be excessive. Benzinga analyst price target report
• Positive Sentiment: Enovis entered into a binding offer to acquire eCential Robotics, a developer of surgical robotics and enabling technologies, for approximately €155 million, or about $180 million. The deal would add robotic automation to Enovis’ ASTRA platform and could broaden its medical-device portfolio, improve surgical workflows and support future growth. Enovis announces eCential Robotics acquisition
• Neutral Sentiment: Management discussed the transaction and its strategic rationale in an M&A call, giving investors more detail on the planned expansion into surgical robotics. The near-term financial impact and execution timeline remain key areas for investors to evaluate. Enovis M&A call transcript
• Neutral Sentiment: Enovis is scheduled to participate in the Wells Fargo Healthcare Conference on September 8, potentially providing additional commentary on the acquisition, growth strategy and financial outlook. Enovis Wells Fargo Healthcare Conference announcement
• Negative Sentiment: The acquisition announcement triggered a steep decline in ENOV shares. Investors appear concerned about the $180 million purchase price, the risks of integrating eCential Robotics and the uncertainty surrounding commercialization of its surgical robot. Enovis shares fall after eCential Robotics offer

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source